Cargando…

Integration analysis of tumor metagenome and peripheral immunity data of diffuse large-B cell lymphoma

BACKGROUND/PURPOSE: It has been demonstrated that gut microbes are closely associated with the pathogenesis of lymphoma, but the gut microbe landscape and its association with immune cells in diffuse large B-cell lymphoma (DLBCL) remain largely unknown. In this study, we explored the associations be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yu, Han, Shuiyun, Xiao, Xibing, Zheng, Lu, Chen, Yingying, Zhang, Zhijian, Gao, Xinfang, Zhou, Shujuan, Yu, Kang, Huang, Li, Fu, Jiaping, Hong, Yongwei, Jiang, Jinhong, Qian, Wenbin, Yang, Haiyan, Shen, Jianping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10206395/ https://www.ncbi.nlm.nih.gov/pubmed/37234150 http://dx.doi.org/10.3389/fimmu.2023.1146861

Ejemplares similares

Zanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma
por: Yuan, Xianggui, et al.
Publicado: (2022)

The gut microbiota correlate with the disease characteristics and immune status of patients with untreated diffuse large B-cell lymphoma
por: Lin, Zhouning, et al.
Publicado: (2023)

Low GILT Expression is Associated with Poor Patient Survival in Diffuse Large B-Cell Lymphoma
por: Phipps-Yonas, Hannah, et al.
Publicado: (2013)

Aberrantly Activated APOBEC3B Is Associated With Mutant p53-Driven Refractory/Relapsed Diffuse Large B-Cell Lymphoma
por: Zhang, Xuzhao, et al.
Publicado: (2022)

Exploring the molecular mechanisms and shared gene signatures between rheumatoid arthritis and diffuse large B cell lymphoma
por: Li, Haoguang, et al.
Publicado: (2022)

International Prognostic Index-Based Immune Prognostic Model for Diffuse Large B-Cell Lymphoma
por: Mu, Shidai, et al.
Publicado: (2021)

CD19-Targeted Immunotherapies for Diffuse Large B-Cell Lymphoma
por: Gambella, Massimiliano, et al.
Publicado: (2022)

Risk of HBV reactivation in relapsed or refractory diffuse large B-cell lymphoma patients receiving Bruton tyrosine kinase inhibitors therapy
por: Ni, Ying, et al.
Publicado: (2022)

The Prognostic Utility of (18)F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography-Based Analyses of Metabolic Response Rates in Newly Diagnosed Diffuse Large B Cell Lymphoma Patients
por: Li, Cong, et al.
Publicado: (2022)

Nonclassical Monocytes Are Prone to Migrate Into Tumor in Diffuse Large B-Cell Lymphoma
por: Le Gallou, Simon, et al.
Publicado: (2021)

Impact of initial chemotherapy cycles and clinical characteristics on outcomes for HIV-associated diffuse large B cell lymphoma patients: The Central and Western China AIDS Lymphoma League 001 study (CALL-001 study)
por: Wang, Chaoyu, et al.
Publicado: (2023)

Editorial: Novel treatments for diffuse large B-cell lymphoma: The post-CART era
por: Mussetti, Alberto, et al.
Publicado: (2022)

Cord blood-derived CD19-specific chimeric antigen receptor T cells: an off-the-shelf promising therapeutic option for treatment of diffuse large B-cell lymphoma
por: Yu, Tiantian, et al.
Publicado: (2023)

A 9-LncRNA Signature for Predicting Prognosis and Immune Response in Diffuse Large B-Cell Lymphoma
por: Wang, Xiaoxuan, et al.
Publicado: (2022)

The causal effect of inflammatory bowel disease on diffuse large B-cell lymphoma: two-sample Mendelian randomization study
por: Lu, Chuanyang, et al.
Publicado: (2023)

Peripheral blood lymphocyte to monocyte ratio recovery from low levels at diagnosis after completion of first line therapy predicts good clinical outcomes in patients with diffuse large B-cell lymphoma
por: Zhou, Shujuan, et al.
Publicado: (2017)

Oncogenic Mutations and Tumor Microenvironment Alterations of Older Patients With Diffuse Large B-Cell Lymphoma
por: Zhu, Yue, et al.
Publicado: (2022)

Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the CART Era
por: González Barca, Eva
Publicado: (2022)

Distinct Molecular Subtypes of Diffuse Large B Cell Lymphoma Patients Treated with Rituximab-CHOP Are Associated with Different Clinical Outcomes and Molecular Mechanisms
por: Yu, Haifeng, et al.
Publicado: (2021)

Sinonasal diffuse large B-cell lymphoma in a patient with Wiskott–Aldrich syndrome: A case report and literature review
por: Sun, Xiwen, et al.
Publicado: (2023)

Novel Immune-Based treatments for Diffuse Large B-Cell Lymphoma: The Post-CAR T Cell Era
por: Atallah-Yunes, Suheil Albert, et al.
Publicado: (2022)

Identification of lactate regulation pattern on tumor immune infiltration, therapy response, and DNA methylation in diffuse large B-cell lymphoma
por: Wang, Jinghua, et al.
Publicado: (2023)

Peripheral immune cell profiling of double-hit lymphoma by mass cytometry
por: Lei, Tao, et al.
Publicado: (2023)

Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients
por: Qu, Changju, et al.
Publicado: (2022)

Case Report: Combined Intravenous Infusion and Local Injection of CAR-T Cells Induced Remission in a Relapsed Diffuse Large B-Cell Lymphoma Patient
por: Hu, Linhui, et al.
Publicado: (2021)

Diffuse Large B-Cell Lymphoma of the Mandible Diagnosed by Metagenomic Sequencing: A Case Report
por: Liu, Kaili, et al.
Publicado: (2021)

EBF1, MYO6 and CALR expression levels predict therapeutic response in diffuse large B-cell lymphomas
por: Turdo, Alice, et al.
Publicado: (2023)

Comparison of Chemotherapy Combined With Chidamide Versus Chemotherapy in the Frontline Treatment for Peripheral T-Cell Lymphoma
por: Wang, Jinni, et al.
Publicado: (2022)

T Cell Defects: New Insights Into the Primary Resistance Factor to CD19/CD22 Cocktail CAR T-Cell Immunotherapy in Diffuse Large B-Cell Lymphoma
por: Wang, Jiachen, et al.
Publicado: (2022)

Diffuse large B-cell lymphoma microenvironment displays a predominant macrophage infiltrate marked by a strong inflammatory signature
por: Serna, Leyre, et al.
Publicado: (2023)

CAR T-Cell Therapy Predictive Response Markers in Diffuse Large B-Cell Lymphoma and Therapeutic Options After CART19 Failure
por: Caballero, Ana Carolina, et al.
Publicado: (2022)

Comparison of first-line treatments for elderly patients with diffuse large B-cell lymphoma: A systematic review and network meta-analysis
por: Wang, Yangyang, et al.
Publicado: (2023)

CCL8 as a promising prognostic factor in diffuse large B-cell lymphoma via M2 macrophage interactions: A bioinformatic analysis of the tumor microenvironment
por: Lou, Xiaoli, et al.
Publicado: (2022)

Case Report: Dual Inhibition of HDAC and BTK for Diffuse Large B-Cell Lymphoma After Failure to CD19-Targeted CAR-T Therapy
por: Zhu, Weiguo, et al.
Publicado: (2022)

Degree of stemness predicts micro-environmental response and clinical outcomes of diffuse large B-cell lymphoma and identifies a potential targeted therapy
por: Hu, Fang, et al.
Publicado: (2022)

Prognostic impact of peripheral natural killer cells in primary central nervous system lymphoma
por: Lin, Zhiguang, et al.
Publicado: (2023)

Prognostic significance of the red blood cell distribution width in diffuse large B-cell lymphoma patients
por: Zhou, Shujuan, et al.
Publicado: (2017)

Prognostic value of prelymphodepletion absolute lymphocyte counts in relapsed/refractory diffuse large B-cell lymphoma patients treated with chimeric antigen receptor T cells
por: Lu, Yanyan, et al.
Publicado: (2023)

The frequency of differentiated CD3(+)CD27(-)CD28(-) T cells predicts response to CART cell therapy in diffuse large B-cell lymphoma
por: Worel, Nina, et al.
Publicado: (2023)

Signet ring cell-like diffuse large B-cell lymphoma involving the breast: a case report
por: Zhang, Lu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_po2ooiomgsfuu1553fcsi0jklk